Top-Down Proteomics with Mass Spectrometry Imaging: A Pilot Study towards Discovery of Biomarkers for Neurodevelopmental Disorders

Hui Ye1,2,3, Rakesh Mandal4, Adam Catherman5, Paul M. Thomas5, Neil L. Kelleher5, Chrysanthy Ikonomidou4, Lingjun Li5,6*

1 State Key Laboratory of Natural Medicines, Key Lab of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing, PR China, 2 Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, PR China, 3 School of Pharmacy, University of Wisconsin Madison, Madison, Wisconsin, United States of America, 4 Department of Neurology, University of Wisconsin Madison, Madison, Wisconsin, United States of America, 5 Proteomics Center of Excellence, Northwestern University, Evanston, Illinois, United States of America, 6 Department of Chemistry, University of Wisconsin Madison, Madison, Wisconsin, United States of America

Abstract
In the developing mammalian brain, inhibition of NMDA receptor can induce widespread neuroapoptosis, inhibit neurogenesis and cause impairment of learning and memory. Although some mechanistic insights into adverse neurological actions of these NMDA receptor antagonists exist, our understanding of the full spectrum of developmental events affected by early exposure to these chemical agents in the brain is still limited. Here we attempt to gain insights into the impact of pharmacologically induced excitatory/inhibitory imbalance in infancy on the brain proteome using mass spectrometric imaging (MSI). Our goal was to study changes in protein expression in postnatal day 10 (P10) rat brains following neonatal exposure to the NMDA receptor antagonist dizocilpine (MK801). Analysis of rat brains exposed to vehicle or MK801 and comparison of their MALDI MS images revealed differential relative abundances of several proteins. We then identified these markers such as ubiquitin, purkinje cell protein 4 (PEP-19), cytochrome c oxidase subunits and calmodulin, by a combination of reversed-phase (RP) HPLC fractionation and top-down tandem MS platform. More in-depth large scale study along with validation experiments will be carried out in the future. Overall, our findings indicate that a brief neonatal exposure to a compound that alters excitatory/inhibitory balance in the brain has a long term effect on protein expression patterns during subsequent development, highlighting the utility of MALDI-MSI as a discovery tool for potential biomarkers.

Citation: Ye H, Mandal R, Catherman A, Thomas PM, Kelleher NL, et al. (2014) Top-Down Proteomics with Mass Spectrometry Imaging: A Pilot Study towards Discovery of Biomarkers for Neurodevelopmental Disorders. PLoS ONE 9(4): e92831. doi:10.1371/journal.pone.0092831

Editor: Axel Imhof, Ludwig-Maximilians-Universität München, Germany

Received February 27, 2014; Accepted April 7, 2014; Published April 7, 2014

Copyright: © 2014 Ye et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported in part by University of Wisconsin grants PRJ-26CH, PRJ-23FA, PRJ-25AH and Waisman grant PRJ 233-23CK to CI, a core grant to the Waisman Center from the National Institute of Child Health and Human Development (P30 HD03352), the National Institutes of Health (NIH) grant (R01DK071801 to LL). The authors would also like to acknowledge NIH shared instrument program for funding the instrument purchase (S10 RR029531 to LL). NLK thanks support from NIH grants R01 GM067193 and P30 DA018310 and the Searle Funds at the Chicago Community Trust (to Chicago Biomedical Consortium). LL acknowledges an H. L. Romnes Faculty Research Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: ikonomidou@neurology.wisc.edu (CI); lli@pharmacy.wisc.edu (LL)

Introduction
Sedatives, anesthetics and anticonvulsants, such as ketamine, nitrous oxide (laughing gas), propofol, sevoflurane, benzodiazepines and barbiturates are used frequently in obstetric and pediatric medicine. Neurodevelopmental abnormalities associated with developmental exposure to such drugs and to environmental toxins, such as ethanol, have been reported. It has been suggested that disturbances in neurotransmitter signalling during critical periods can redirect subsequent development. Deterimental long-term effects observed in humans range from mild neurobehavioral disturbances (hyperactivity/attention deficit and learning disabilities) to severe mental retardation and autism spectrum disorders (ASD) [1,2]. Interestingly, a potential unifying explanation for the pathogenesis of ASD is the disruption of excitatory/inhibitory circuit balance during critical periods of development [3]. Excitatory/inhibitory neurotransmission balance is important for single neurons to acquire multiple functional properties through an experience-dependent maturation process, which occurs during critical periods of brain development.

Previously we provided evidence that excitation/inhibition imbalance in early development can cause long lasting changes of the brain proteome [4]. In addition, compounds which inhibit NMDA receptors or activate γ-aminobutyric acid A (GABA A) receptors and cause excitation/inhibition imbalance, can induce widespread neuroapoptosis in the developing rodent brain, inhibit neurogenesis [5] and cause impairment of learning and memory [6]. Interestingly, early disruption of excitatory/inhibitory balance in infant mice (P0–P7) via blockade of NMDA receptors or activation of GABA A receptors caused very similar acute and long-term changes of the cerebral proteome [4]. Changes of the cortex proteome one day (P7), one week (P14) and four weeks (P35) following treatment at P6 suggest that short period suppression of synaptic neurotransmission during critical periods of brain development causes long lasting dysregulation of proteins associated with apoptosis, oxidative stress, inflammation, proliferation...
and neuronal circuit formation [4]. These observations support the hypothesis that early disruption of excitatory/inhibitory balance in the brain interferes with many subsequent critical developmental events.

The integration of gel electrophoresis and liquid chromatography coupled to MS enables more comprehensive characterization of complex proteomes to detect disease biomarkers [7,8,9,10] or evaluate the response to stress or to the exposure of compounds of interest [11,12,13,14]. Previous studies of Kaindl et al. examined the whole cortex proteome after treatment with MK801 in infancy using this conventional approach [4], yet more precise localization of the detected protein expression changes has not been conducted. Moreover, our previous observation of MK801-treated rat brains visualized by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) exhibited a marked increase of neuron apoptosis in specific brain regions other than cortex, dictating the demand for a global examination of the entire brain to discover putative protein biomarkers related to the apoptotic process. Conventional immunohistochemical (IHC) staining allows for obtaining high resolution distribution images of targeted proteins. However, a significant limitation to this method is the need for labeling, which means that the target molecules must be known prior to the experiment. Alternatively, mass spectrometric imaging (MSI) has evolved as a powerful tool based on matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS). This technique allows for the determination of the mass and location of biomolecules directly from a tissue sample [15,16,17,18]. MALDI MSI has enormous advantages over conventional protein imaging techniques in that not only is it label-free but also it enables simultaneous mapping of numerous molecules in tissue samples with great sensitivity and chemical specificity. MALDI MSI has proven to be a valuable technology with numerous applications in localizing proteins [19,20,21,22], examining lipid distributions [23,24], mapping neuropeptides [25,26] and imaging drugs or metabolites [27] at both organ and cellular levels by varying the experimental conditions. Since no prior knowledge of molecular identities is required for MSI applications, it has become a useful biomarker discovery tool to compare analyte expression pattern changes by analyzing multiplexed data sets. For example, Minerva et al. evaluated the capability of MALDI-MS to study peptide expression patterns in the mouse pancreas under normal and pathological conditions and identified a peptide marker, the C-peptide of insulin, which was dramatically up-regulated in obese mice [28]. Sköld et al. observed a significant decrease of a large neuron-specific peptide, PEP-19, in a mouse model of Parkinson’s disease (PD) using MALDI-MSI [29]. Hanrieder et al. quantified relative abundances of striatal neuropeptides in a rat model of L-DOPA-induced dyskinesia (LID) and revealed several upregulated dynorphins and enkephalins in the dorsolateral striatum of high-dyskinetic rats [30]. Two prodynorphin derived peptides, dynorphin B and δ-neoendorphin, were positively associated with LID severity. Li and Hummon further explored the application of MALDI-MSI to image proteins from 3D colon carcinoma cell cultures and visualized cytochrome C and histone H4 in the cell spheroid [31]. In clinical settings, MALDI MSI has successfully enabled discovery of tissue biomarkers for diseases such as myxoid sarcomas [32], adenocarcinoma [33], gastric cancer [34], hypertension [35], metastatic melanoma [36] and prostate cancer [20]. These findings underscore the critical role MALDI-MSI plays in the study of peptide/protein dynamics in the context of human diseases. With MSI, a better understanding of the molecular pathology of various diseases such as cancer and neurodegenerative diseases can be obtained.

Although the discrimination of protein expression patterns of tissues harvested from disease and normal animals could be accomplished by MALDI-MSI, it remains to be a bottleneck to identify proteins via MALDI-MSI alone due to limited fragmentation obtained from the singly charged high-mass species except fairly abundant ones [37]. Bottom-up MS of tryptic-digested proteins via in situ enzymatic digestion [38] or in-solution tissue extract digestion [39] is commonly attempted to interpret peaks with protein identities. Nevertheless, matching bottom-up identified peptides with intact proteins, especially those with isoforms, detected by MALDI-MSI is significantly challenging. Alternatively, recent advances in top-down MS and various dissociation methods facilitate the process by offering capability to fragment and ultimately identify intact proteins. Recent studies have shown that tissue extraction, fractionation followed by top-down tandem MS allows for direct identifications of intact proteins [19,40,41,42]. For example, Meistermann unambiguously identified transthyretin (Ser52-Gln140) as a potential toxicity biomarker in kidneys of rats that were administered the nephrotoxin gentamicin [41]. Lagarrigue identified seven potential biomarkers of childhood absence epilepsy as Synapsin-1 fragments [43]. Stella et al. and Schey et al. both localized and assigned identities of lens proteins and their truncated forms using a combined MALDI MSI and top-down proteomics approach, a task difficult to complete via a bottom-up approach [44,45].

Herein, we employed MALDI-MSI profiling to investigate region specific changes in the brain proteome following blockade of NMDA receptors in infancy and employed MALDI-MSI to localize these differentiating proteins with relatively high spatial resolution. In the present study, we first identified 22 potential protein biomarkers using this combined strategy. We then extracted proteins from tissues followed by RP HPLC fractionation and top-down sequencing by high resolution tandem MS for confident protein identification.

Materials and Methods

Chemicals and materials

Methanol, acetonitrile, formic acid and gelatin were purchased from Fisher Scientific (Pittsburgh, PA). All water used in this study was Milli-Q water from a Millipore filtration system (Bedford, MA).

Animal Experiments

All animal procedures were reviewed and approved by the Institutional Animal Care and Use Committee (IACUC) of the Graduate School of the University of Wisconsin-Madison. Animal care facilities and procedures are yearly inspected and accredited by AAALAC (A3368-01). Wistar rats were injected i.p. with the NMDA receptors antagonist dizocilpine ((+)-MK801; Tocris, Bristol, UK) 1 mg/kg i.p. on P2 and P4. An equal number of sex-matched littermates that received vehicle (normal saline) served as controls. Rats were terminally anesthetized with 5% isoflurane, transcardially perfused under deep anesthesia with cold saline solution for 5 min at room temperature and immediately decapitated on P10 (N = 4 per group).

Sample Preparation for MALDI-MS

Rat brains were dissected out freshly and cut along the midline to halves. Then the hemispheres were immediately embedded into gelatin solution (100 mg/ml) and snap-frozen in −80°C freezer for further processing. The time between decapitation and freezing of the tissue did not exceed 5 min. Sagittal sections were acquired at a thickness of 12 µm on a cryostat (HM525, Thermo Fisher Scientific).
Scientific, Waltham, MA) and four sections from each animal were deposited onto indium tin oxide (ITO) coated conductive glass slides (Delta Technologies, Loveland, CO) as technical replicates. Tissue sections were immersed in 70% ethanol for 1 min and another 95% ethanol bath for 1 min for protein fixation and lipid removal. The sections were then allowed to dry for 30 min under vacuum. For profiling purpose, matrix deposition was conducted manually with a pipette directly on tissue sections. 300 nL of freshly prepared 20 mg/ml sinapinic acid (Sigma Aldrich, St. Louis, MO) dissolved in 50% acetonitrile, 0.1% formic acid were sequentially deposited onto 14 regions of a brain section. For imaging purposes, 20 mg/ml sinapinic acid dissolved in 50% acetonitrile, 0.1% formic acid was sprayed onto a brain section homogenously using an airbrush held 35 cm from the tissue. Five coats were applied and the spray duration for each coat was 30 s with 1 min dry time between each cycle.

**MALDI-MS Profiling and Imaging**

MALDI-MS profiling spectra of the manually spotted tissue sections and imaging data of intact brain sections were acquired on an Autoflex III MALDI-TOF/TOF mass spectrometer (Bruker Daltonics, Billerica, MA) equipped with a 200 Hz smart beam laser. The following parameters were adopted in the positive linear mode at a mass range of 3-25 kDa for spectral acquisition with a delayed extraction of 30 ns: ion source 1 voltage 20.00 kV, ion source 2 voltage 18.55 kV, lens voltage 6.80 kV and pulsed ion extraction 190 ns. Protein calibration standard I (Bruker Daltonics, Billerica, MA) was used to externally calibrate the instrument before data acquisition. Briefly, 2000 consecutive laser shots were accumulated for each deposited matrix droplet. The profiling spectra were smoothed and baseline subtracted using flexAnalysis (Bruker Daltonics, Billerica, MA). As for imaging, automated MSI acquisitions of the brain sections were controlled by flexImaging software (Bruker Daltonics, Billerica, MA). Array of spectra was collected at 200 μm intervals in both x and y dimensions, and each spectrum consists of 200 laser shots.

**MALDI-MS Data Analysis**

The MATLAB-supported software ClinProTools 2.2 (Bruker Daltonics, Billerica, MA) enables baseline subtraction, normalization, peak calibration, spectral alignment and statistical analyses of the resulting profiling spectra. The profiling spectra were divided as the vehicle-treated and the MK801-treated class and loaded into the software following the generation of relevant XML files with a ClinProSpectraImport generator. The opened XML files were then prepared by recalibration, average peak list calculation, and peak calculation. By averaging, a single representative spectrum composed of 14 discrete spots from each section was generated for each class, which was used in all of the statistical analyses. The profiling spectra from the two classes were also compared region-wise for evaluating the sensitivity of cells in various regions in response to the MK801 treatment. Four serial sections were collected and profiled for four animals, with their intensities averaged for each group. PCA plot and loading plot were generated for each comparison group (N = 4). Peak statistics exported the mass, mass deviation, averaged intensities, the P value of Anderson-Darling test (PAD), the P value of the Wilcoxon test/Kruskal-Wallis test (PWKW) and P value of the t test/ANOVA (PTTA) of the individual peaks, whereas PTTA was used throughout this study. Models of control and treated groups were generated using available algorithm, genetic algorithm, where the minimum number of peaks was set at 10 and the maximum set as “default”. The recognition capability and cross validation were calculated to 98.50% and 91.50%, indicating the reliability and accuracy of the generated model.

For image processing, the Bruker proprietary software flexImaging 3.0 (Bruker Daltonics, Billerica, MA) was utilized to generate MS images and overlay the optical image with the MS images for good visualization. One section from each sacrificed animal was collected (N = 4) and MS images were acquired from sections collected from animals of two classes. MSI data were also imported into ClinProTools to analyze differences in abundance of proteins in the two animal groups. For comparison, specific regions of interest (ROI) were selected manually and the spectra resulting from the ROI were averaged and compared in ClinProTools. PCA plots and loading plots were generated for each comparison group.

**Liquid-phase Protein Extraction and Fractionation**

Hemisphere of rat brain was manually homogenized in acidified methanol (1:9:90 acetic acid/water/methanol) at a 1:5 ratio (tissue/buffer, v/v) on ice. The extract was centrifuged at 16,100 ref for 10 min in an Eppendorf 5415 D microcentrifuge (Brinkman Instruments), and the resulting supernatant was collected followed by vacuum drying. The mixture was then resuspended in 30 μL of water containing 0.1% formic acid and separated on a 2.1x100 mm Phenomenex Kinetex 2.6 μm particle C18 reversed phase (RP) HPLC column using a 60 min gradient with a flow rate at 0.3 mL/min. Fractions were collected every three minutes and concentrated in a Savant SC 110 SpeedVac concentrator (Thermo Electron Corporation, West Palm Beach, FL). The intact protein fractions were reconstituted in 0.1% formic acid and screened by MS profiling using MALDI-TOF/TOF via on-plate mixing with sinapinic acid. The spots were analyzed according to previous instrumentation settings and matched to m/z values obtained with in situ tissue profiling.

**On-line Top-down MS/MS using Nano-LC-ESI-LTQ-Orbitrap Elite**

The fractions that contained peaks of interest were further analyzed by on-line top-down MS on an Ultimate 3000 RSLCnano system coupled to an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Bremen, Germany). Fractions of interest (0.5 μL) were injected onto a 2 cm, 150 μm i.d. PLRP-S (dp 5 μm, pore size 100 Å) trap column. A 10 cm, 75 μm i.d. PLRP-S column was used for separation. The mobile phases used were: deionized water with 0.1% formic acid (A); acetonitrile with 0.1% formic acid (B). The gradient was delivered at 300 nL/min starting at 5% B and rose to 10% B at 7 min, 50% B at 50 min, and 85% B at 58 min. The mass spectrometer was operated in a data-dependent mode, performing higher-energy C-trap collision induced dissociation (HCD)-MS² (scan 1), conventional collision induced dissociation (CID)-MS² (scan 2) and electron transfer dissociation (ETD)-MS² (scan 3) on each of the Top 3 precursors (selected by intact mass) in a FT-MS precursor scan. More details on mass spectrometric acquisition parameters can be found in Method S1 in File S1.

Data were deisotoped with Xtract using the cRAWler algorithm (Thermo Fisher, Bremen, Germany) and searched with a custom 168-core ProSightPC 3.0 cluster (ThermoFisher, Bremen, Germany) using an iterative search tree. The detailed information on search tree can be found in Method S1 in File S1. ProSightPC Warehouses were created against the UniProt 2011_04 build filtered for Rattus norvegicus (TaxId: 10116). The “simple” rat database was created with all base sequences (signal peptide cleavage products, alternative splice forms, etc) and N-terminal acetylation applied. The simple database has 33,998 base
sequences and 109,973 modified forms. The "complex" rat database contains all of the information in the simple database in addition to the annotated post-translational modifications in UniProt. The complex database had 40,990 base sequences and 3,616,723 modified forms. All retrieved proteins are considered as positive identification if: (a) an expect score (E value) less than $10^{-5}$, and (b) mass error ($\Delta m$) less than 5 ppm between the calculated and expected intact masses [46]. The protein m/z observed on MALDI-MS, entry name, accession number, protein identity, calculated mass deconvoluted from the m/z observed on LTQ Orbitrap, expected mass, average mass, post translational modifications (PTMs) present in the sequence and E value of the search results are all listed in Table 1–2 and Table S1, S2 in File S1. The fragment ions assignments for identified proteins were summarized in File S2 (top-down MSMS fragmentation), whereas the raw MS/MS spectra were recorded in File S3 (top-down MSMS spectra).

Results

In this study, we used a combined profiling and imaging strategy as illustrated in Figure 1 to identify the differentially expressed proteins in the vehicle and MK801 treated rat brains. Profiling involves manually depositing matrix onto the regions of interest of the brain section and analyzing the section region by region, whereas imaging requires the whole tissue section to be coated with a homogenous matrix layer and scanned according to a predefined array.

In situ Profiling of the Vehicle- and MK801-treated Infant Rat Brains

For high-throughput profiling, four sections from each of the four pairs of sex-matched P10 infant rat brains that had undergone treatment with saline as the control group (N = 4) and MK801 as the treated group (N = 4) were compared. Each section was manually profiled with fourteen spots representing the corresponding major anatomical structures in a rat brain sagittal section. Specifically, the fourteen major regions were divided based on rat brain atlas (www.brainmaps.org) as designated in Fig. 1C, including olfactory bulb as region #1, accumbens nucleus (Acb) as region #3, cortex as region #2, 5, 9 and 12, corpus callosum (cc) as region #4, hypothalamus (Hypo) as region #6, thalamus (TH) as region #7, hippocampus (Hippo) as region #8, medulla as region #10, colliculi as region #11, pons as region #13 and cerebellum as region #14. Spectra produced from profiling the fourteen brain regions clearly differentiate the anatomical regions as previously reported. More importantly, the MS profiles of proteins from each of the regions were compared between infant rat brains treated with vehicle and MK801 with statistical support provided by ClinProTools. The differences of peaks were evaluated by m/z, signal intensity and p value. Although most of the masses found in the two classes resemble each other, the overlaid representative spectra from the two classes displayed differential abundance levels of several peaks in the control as the green trace and the treated samples as the red trace shown in Fig. 2A. The enlarged spectra are displayed in Fig. 2B–E. Fig. 2B displays the peaks at m/z 8468 and 8366. In this panel, the former peak exhibited relatively the same abundance between the two groups, whereas the latter was significantly upregulated in the averaged spectra acquired from MK801-treated rat brains. Figure 2C shows another peak at m/z 6718, the abundance of which was also greatly increased in the MK801 treated group, nevertheless, the peak at m/z 6649 was detected at almost the same intensity in the two groups. In contrast with Fig. 2B and 2C, Fig. 2D and Fig. 2E exhibit two ions at m/z 15825 and m/z 16792 that were both down-regulated in the MK801-treated group. Technical replicates within each animal group were averaged and the mean values of each group were used to perform statistical test. More proteins differentially expressed in the control compared with the treated samples are summarized in Table 1 with the information of observed m/z, PTTA between the two groups and their relative abundance ratio. The low $P$ values obtained from PTTA suggest that the observed differences of the individual peaks’ abundances are statistically significant and are not due to coincidence. This result demonstrates that the peaks as detailed in Table 1 can be used to differentiate the control from the treated group. Based on previous MALDI-MS literature [29,41,47] and database search in UniProt, several peaks that exhibited differential abundance levels after MK801 treatment were mass-matched to proteins with a mass error tolerance of ±4 Da. For example, the proteins displayed higher abundances in the treated group were assigned as ubiquitin at m/z 8566 as shown in Figure 2B and PEP-19 at m/z 6718 as displayed in Figure 2C, whereas the protein at m/z 6649 that displayed the same abundance level following the treatment was assigned as cytochrome c oxidase subunit 6a-L as in Fig. 2C. In contrast, the protein that exhibited decreased abundance in the MK801-treated rat brains was identified as calmodulin with m/z 16792 in Fig. 2E. Although MALDI-MS has demonstrated its capability of providing accurate m/z of the protein species present in rat brain sections for identification, the identities of the molecules that have not been reported, such as the peaks at m/z 8468 and 15825 in Fig. 2B and 2D, could not be assigned due to the lack of sequence-specific fragmentation information. A comprehensive strategy that combines MALDI-MS with high resolution top-down MS/MS sequencing was employed for protein identification and will be discussed in the following section.

Mapping the Spatial Distribution of Peaks of Differential Expression Patterns from the Vehicle- and MK801-treated Infant Rat Brains

Although the profiling strategy provides high throughput information regarding regional differences, MSI allows for mapping of the ions of interest in the entire rat brain section with much higher spatial resolution than regional profiling. Overall, the average spectra for the imaged brain sections of MK801 treated rats exhibited great similarities to those of vehicle-treated rats, agreeing well with the average profiling spectra. Nevertheless, the differential features highlighted in the profiling approach were confirmed through MSI using one rat brain section from each group as depicted in Fig. 1E. Additionally, statistical software also aids in validating the potential biomarkers that displayed differential expression levels in the vehicle and treated groups. For example, the profiling spectra showed that the ion at m/z 6718 exhibited significant up-regulation by 1.8 fold in the MK801-treated group compared to the vehicle-treated one as in Table 1. More specifically, regions #1, #2, #5, #9, #7 and #14 displayed the most drastic changes after the treatment (Fig. 3A). Figure 3B is an optical image of a rat brain section that underwent MSI experiments. As highlighted in Figure 3B, region #2, #5 and #9 correspond to the frontal and cingulate cortex, and region #1, #7 and #14 are registered to the olfactory bulb, TH and cerebellum, respectively. Among all the regions, olfactory bulb as region #1 exhibited the most prominent changes with a 2.5 fold increase comparing to roughly 1.5 fold as shown by other regions. This observation was confirmed by imaging data as shown in Figure 3C. Figure 3C shows two MS spectra averaged specifically from ROI 1 and ROI 2 in Figure 3E, which
| m/z on MALDI-MS | Entry | Accession | Protein Identity | Calc’d Mass (Da) | Exp’d Mass (Da) | Δ Mass (ppm) | Average Mass (Da) | PTTA | Ratio (MK/Veh) |
|----------------|-------|-----------|------------------|------------------|----------------|-------------|------------------|------|----------------|
| 6718           | PCP4_RAT | P63055 | PEP-19           | 6714.25          | 6714.26        | -1          | 6718.19          | <0.001 | 1.8            |
| 11367          | Unknown           |           |                   |                  |                |             |                  |      |                |
| 8566           | RS27A_RAT | P62982 | Ubiquitin         | 8559.61          | 8559.62        | -1          | 8564.76          | <0.001 | 1.6            |
| 5634           | Acyl-CoA-binding protein |      |                   |                  |                |             |                  |      |                |
| 9939           | ACBP_RAT | P11030 | Thymosin β-4      | 9932.12          | 9932.12        | 0           | 9938.19          | <0.001 | 1.4            |
| 9979           | D3ZD09_RAT | D3ZD09 | Cytochrome c oxidase subunit 6b | 9971.80 | 9971.82 | -2 | 9978.17 | <0.001 | 1.4 |
| 5486           | B2RYT3_RAT | B2RYT3 | Cytochrome c oxidase subunit 7c | 5481.87 | 5481.87 | 0 | 5485.40 | <0.001 | 1.3 |
| 8368           | C6C2_RAT | P11951 | Cytochrome c oxidase subunit 6C |                  |                |             |                  | <0.001 | 1.2            |
| 10283          | TIM8_RAT | Q9VFW97 | Mitochondria import inner membrane translocase | 10276.08 | 10276.09 | -1 | 10282.66 | <0.05 | 1.2 |
| 9193           | TIM8B_RAT | P62078 | Adenylate cyclase type 10 | 9187.44 | 9187.45 | -1 | 9193.22 | <0.01 | 1.2 |
| 9727           | ACBP_RAT | P11030 | Acyl-CoA-binding protein |                  |                |             |                  | <0.001 | 1.1            |
| 8040           | UCBL1_RAT | P20788 | Cytochrome b-c1 complex subunit | 8035.38 | 8035.38 | 0 | 8040.30 | <0.05 | 1.1 |
| 4936           | TYB10_RAT | P63312 | Thymosin beta-10 | 4933.51 | 4933.52 | -2 | 4939.47 | <0.05 | 1.1 |
| 3430           | ATP5J_RAT | P21571 | ATP synthase-coupling factor 6 | 3426.89 | 3426.90 | 0 | 3428.94 | <0.05 | 0.9 |
| 16792          | CALM_RAT | P62161 | Calmodulin        | 16779.82         | 16779.81       | 1           | 16790.32         | <0.01 | 0.9            |
| 3717           | Q5U2U9_RAT | Q5U2U9 | CCR4-NOT transcription complex, subunit 8 | 3713.87 | 3713.88 | -3 | 3716.25 | <0.01 | 0.9 |
| 3891           | PCSK1_RAT | Q9OQU9 | ProSAAS           | 3888.04          | 3888.04        | 0           | 3890.32          | <0.05 | 0.9            |
| 4800           | SCG2_RAT | P10362 | Secretogranin-2   | 4796.37          | 4796.37        | 0           | 4799.25          | <0.01 | 0.9            |
| 4854           | VGF_RAT | P20156 | Neurosecretory protein VGF | 4850.41 | 4850.41 | 0 | 4853.24 | <0.05 | 0.9 |
| 15825          | SODC_RAT | P07632 | Superoxide dismutase [Cu-Zn] | 15810.82 | 15810.75 | 0 | 15820.33 | <0.05 | 0.8 |
| 11348          | Unknown           |           |                   |                  |                |             |                  |      | <0.001 | 0.6 |

- The italicized protein sequences have been verified by top-down tandem mass spectrometry. The rest of the identity assignments are solely based on mass matching. The proteins that can be identified by neither approach were shown as unknown.
- The bolded sequences represent the proteins that were reported from rat brain in a MALDI-MS-based platform for the first time.
- The bolded sequences represent the proteins that were further identified by top-down MS/MS and annotated with UniProt entry, accession number, calculated mass based on the m/z observed on Orbitrap Elite, expected mass based on the matched protein sequence and the mass difference between the calculated mass and expected mass. All MALDI-MS profiling spectra have been processed by ClinProTools and summarized here by “peak statistic” function. PTTA represents p-value of t-test (2 classes); Ratio represents the relative abundance changes of these proteins in the brain sections of rats treated with MK801 and vehicle, calculated based on the average intensity of the ion observed in the MK801-treated class over the vehicle-treated class.
- doi:10.1371/journal.pone.0092831.t001
Table 2. List of proteins that displayed consistent abundance levels in MK801-treated and vehicle-treated rat brain sections via MALDI-MS.

| m/z on MALDI-MS | Entry       | Accession | Protein Identity       | Calc’d Mass (Da) | Exp’d Mass (Da) | Δ Mass (ppm) | Average Mass (Da) | PTM                        | E value  |
|-----------------|-------------|-----------|------------------------|------------------|-----------------|--------------|------------------|----------------------------|----------|
| 3327            | VIP_RAT     | P01283    | VIP peptides           | 3323.75          | 3323.76         | -3           | 3325.80          | C-term amidation            | 8.3E-14  |
| 3437            | 7B2_RAT     | P27682    | Neuroendocrine protein 7B 2 | 3433.78          | 3433.79         | -3           | 3435.87          |                            | 7.2E-39  |
| 3464            | NPY_RAT     | P07808    | Pro-Neuropeptide Y     | 3460.66          | 3460.66         | 0            | 3462.82          |                            | 1.6E-18  |
| 3593            | 7B2_RAT     | P27682    | Neuroendocrine protein 7B 2 | 3589.89          | 3589.89         | 0            | 3592.06          |                            | 2.5E-60  |
| 3653            | SCG2_RAT    | P10362    | Secretogranin-2        | 3649.80          | 3649.80         | 0            | 3651.94          |                            | 3.8E-67  |
| 3676            | VGF_RAT     | P20156    | Neurosecretory protein VGF | 3672.77          | 3672.78         | -3           | 3674.90          |                            | 8.0E-08  |
| 3871            | VGF_RAT     | P20156    | Neurosecretory protein VGF | 3867.86          | 3867.87         | -3           | 3870.12          |                            | 2.9E-37  |
| 4273            | NPY_RAT     | P07808    | Proneuropeptide Y      | 4269.08          | 4269.08         | 0            | 4271.69          | C-term amidation            | 3.6E-42  |
| 4331            | NPY_RAT     | P07808    | Proneuropeptide Y      | 4327.08          | 4327.09         | -2           | 4329.73          |                            | 1.6E-42  |
| 4522            | TYB10_RAT   | P63312    | Thymosin beta-10       | 4517.33          | 4517.33         | 0            | 4520.04          | N-term acetylation           | 2.2E-70  |
| 4738            | TYB10_RAT   | P63312    | Thymosin beta-10       | 4733.40          | 4733.41         | -2           | 4736.23          | N-term acetylation           | 1.7E-89  |
| 4871            | SCG2_RAT    | P10362    | Secretogranin-2        | 4867.40          | 4867.41         | -2           | 4870.33          |                            | 1.2E-77  |
| 7114            | FILUV9_RAT  | FILUV9    | Uncharacterized         | 7108.52          | 7108.51         | 1            | 7112.62          |                            | 4.9E-42  |
| 8468            | UBB_RAT     | P0CG51    | Polyubiquilin          | 8461.56          | 8461.57         | -1           | 8466.65          | Oxidation                   | 2.9E-35  |
| 8928            | ATF5J_RAT   | P21571    | ATP synthase coupling factor 6 | 8921.55         | 8921.55         | 0            | 8927.06          |                            | 1.7E-52  |
| 10918           | DRB1_RAT    | P62628    | Dynein light chain     | 10909.71         | 10909.72        | -1           | 10916.41         | N-term acetylation, oxidation | 6.2E-36  |
| 12204           | ARP19_RAT   | Q712U5    | cAMP-regulated         | 12196.24         | 12196.26        | -2           | 12203.67         | N-term acetylation           | 2.3E-13  |
| 14428           | O6MGC4_RAT  | Q6MGC4    | H2-K region expressed  | 14417.76         | 14417.73        | 2            | 14426.26         | N-term acetylation, water adduct | 3.1E-24  |

These proteins were all identified by means of top-down tandem MS sequencing on a nanoLC-ESI-LTQ-Orbitrap Elite system.
doi:10.1371/journal.pone.0092831.t002
correspond to the olfactory bulb regions from the vehicle and the MK801 treated rat brain sections, respectively. The peak at m/z 6718 was elevated to roughly 3 fold from the MK801-treated spectrum in comparison to that of a vehicle-treated one, consistent with the profiling results. Moreover, the loading plot shown in Figure 3D suggests that the m/z 6718 peak contributes significantly to the distinction of the two ROIs, especially in load 2, providing statistical evidence to the differentiating role of this ion. Figure 3E displays more straightforward proof by showing the MS images of the m/z 6718 ion obtained from the vehicle and MK801 treated section. The difference in color suggested that the m/z 6718 ion was significantly more concentrated in the olfactory bulb of the MK801 treated section. The cortex also exhibited explicit difference in the vehicle- and the MK801-treated group. Moreover, the abundance of the m/z 6718 ion in TH and cerebellum were also increased as indicated by the MS images.

Figure 1. An overall strategy for mapping proteins in brain tissues by combining MS profiling and imaging. The animals treated with MK801 were sacrificed and handled pairwise (A). The brains were removed and embedded in gelatin (B) followed by sectioning (C). Four sections from each brain were used and 14 regions as annotated in (C) from each section were profiled (D). An entire section was imaged from one brain (E). Four pairs of brains (vehicle vs. MK801) were profiled and imaged (N = 4), respectively, on a MALDI-TOF/TOF instrument (Bruker autoflex III) (F). The profiling spectra were compared pairwise for each specific region (G), and the imaging data were compared as well (H).

doi:10.1371/journal.pone.0092831.g001
The differential expression levels of $m/z$ 6718 in the vehicle and MK801-treated rat brains were reproducibly proven by the integration of profiling and imaging data, demonstrating consistency of our combined strategy.

Other than the $m/z$ 6718 ion, the abundance of the peak at $m/z$ 8566 in the MK801-treated group was elevated by 1.6 fold compared to the vehicle-treated one. Profiling spectra of regions #2, #5, #3, #6, #7 and #14 displayed the most distinguishable changes in expression levels of the $m/z$ 8566 ion as shown in Fig. 4A. As annotated in Figure 4B, regions #2 and #5 are registered as cortex; regions #7 and #14 correspond to TH and cerebellum, respectively; and regions #3 and #6 are assigned as Acb and Hypo. Accordingly, the intensity of the $m/z$ 8566 ion in the MS spectra of the TH regions from the MK801-treated rat was elevated by around 1.4 fold comparing to the vehicle-treated one as indicated in Figure 4C, which agreed well with the increase displayed in Figure 4A. The spectra were averaged specifically from the TH regions of the vehicle and MK801-treated rat brain sections, which were designated as ROI 1 and ROI 2, respectively. Figure 4D shows the statistical loading plot of the two ROIs, indicating that the $m/z$ 8566 ion contributes most significantly to differentiate the TH regions of the two groups in Load 1. The statistical evidence was further supported by the MS images displayed in Figure 4E. Acb as region #3, Hypo as region #6 and cortex as region #2 and #5 all showed significant increase in relative abundance of the $m/z$ 8566 ion in the image obtained from the MK801-treated section compared with the vehicle-treated section, as indicated by the color scale in Figure 4E. TH as region #7 and cerebellum as region #14 also exhibited noticeable increase of concentration in the MK801-treated section compared with the vehicle one. In summary, the utilization of the MALDI-MS profiling and imaging techniques was exemplified by the differentiating peaks at $m/z$ 6718 and 8566, and have been applied to discern the proteins that changed significantly following MK801 treatment due to the reproducibility and consistency of the combined strategy.

**Protein Identification**

Since knowledge about the identity and chemical form of the molecular species of interest is essential to investigate their biological roles, efforts were focused on identifying the peaks that display significantly different expression levels after MK801 treatment. Although the discrimination could be made by combining the imaging and the profiling techniques utilizing MALDI-TOF/TOF, it is significantly more difficult to identify the potential proteins of interest via MALDI-MS alone due to limited fragmentation obtainable from the singly charged high-mass ions produced by MALDI-MS. The initial step of identification was
fulfilled by the conventional fractionation, which helped eliminating ion suppression effects, reducing sample complexity and thus increasing the dynamic range of the analysis. The rat brains were pooled and fractionated in RP HPLC to concentrate the targeted proteins and reduce the complexity arising from high abundance proteins of tissues. All fractions were then screened on MALDI-TOF/TOF with the aim to ascertain if the proteins of interest observed on MALDI-MS from the brain sections were extracted by tissue homogenization and purified by crude fractionation. As shown in Fig. 3A, the peaks of \( m/z \) 6718 and 8566 were detected at high abundance in fraction \#7 and \#10, respectively. The fractions containing the targeted proteins selected via MSI were then analyzed on a nanoLC-ESI-Orbitrap Elite system. The accurate masses provided by this high-end instrument were then

Figure 3. Elevated level of the \( m/z \) 6718 ion quantified by the strategy combining MS profiling and imaging. A) The ratios of the intensities of the ion at \( m/z \) 6718 in the profiling spectra of specific regions, regions \#1, \#2, \#5, \#9, \#7 and \#14, where the ion was concentrated. The averaged intensities and p-values were calculated by ClinProTools and manually confirmed. *, p<0.05; **, p<0.01, unpaired student’s t-test. (B) An optical image of a rat brain section washed after MSI experiments. (C) The \( m/z \) 6718 ion was up-regulated in the averaged MSI spectrum of the olfactory bulbs, ROI 1 and ROI 2, of the rat brain section treated with vehicle and MK801 as shown in (E). (D) A loading plot of ROI 1 and ROI 2 analyzed by ClinProTools. The \( m/z \) 6718 ion was shown to contribute significantly in differentiating the two ROIs in Load 2. (E) MS images of the ions at \( m/z \) 6718 for the vehicle and the MK801-treated rat brain sections. The \( m/z \) 6718 ion was more concentrated in the olfactory bulb, cortex, thalamus (TH) and cerebellum regions in the MK801-treated section compared to the vehicle-treated one. doi:10.1371/journal.pone.0092831.g003

Figure 4. Elevated level of the \( m/z \) 8566 ion quantified by the strategy combining MS profiling and imaging. A) The ratios of the intensities of the ion at \( m/z \) 8566 in the profiling spectra of specific regions, regions \#2, \#5, \#3, \#6, \#7 and \#14, where the ion was concentrated. *, p<0.05; **, p<0.01, unpaired student’s t-test. (B) An optical image of a rat brain section washed after MSI experiments. (C) The \( m/z \) 8566 ion was up-regulated in the averaged MSI spectrum of the thalamus (TH) regions, ROI 1 and ROI 2, of the rat brain section treated with vehicle and MK801 as shown in (E). (D) A loading plot of ROI 1 and ROI 2 analyzed by ClinProTools. The \( m/z \) 8566 ion was shown to contribute significantly in differentiating the two ROIs in Load 1. (E) MS images of the ions at \( m/z \) 8566 for the vehicle and the MK801-treated rat brain sections. The \( m/z \) 8566 ion was more concentrated in the frontal cortex, accumbens nucleus (Acb), thalamus (TH) and cerebellum regions in the MK801-treated section compared to the vehicle-treated one. doi:10.1371/journal.pone.0092831.g004
deconvoluted, and the averaged masses were compared to the masses detected on MALDI-TOF/TOF for mass-matching. Fig. 5B shows a representative MS spectrum, which contains several multiply charged ions, including m/z 611.392 (z = 11), m/z 672.432 (z = 10), m/z 747.836 (z = 9), m/z 840.290 (z = 8), m/z 960.103 (z = 7), m/z 1120.05 (z = 6) and m/z 1343.86 (z = 5). After spectrum deconvolution performed by software Xtract 3.0, these ions were all attributed to the molecule with monoisotopic mass at 6714.25 Da. Moreover, the well-resolved isotopic distribution in the insert of Fig. 5B suggests its neutral average mass at 6717 Da, which could be matched with the singly-charged m/z 6718 peak generated by MALDI-MS. The mass discrepancy between the peaks observed on TOF/TOF and Orbitrap further demonstrates the different resolution provided by two instruments. Followed by mass-matching with the targeted proteins, the selected ions were then subjected to top-down high resolution tandem MS, using a complementary suite of fragmentation techniques: HCD, CID and ETD. Fig. 5C displays the multiple fragmentation spectra arising from the m/z 1120.05 (z = 6) ion using these various techniques. The rich sequence-specific fragment ions produced by the complementary fragmentation techniques were used to search the rat protein database with ProSightPC 3.0. Based on the ultra-high mass resolution (120,000 in MS1 and 60,000 in MS2 at m/z 400) and accuracy (mass error smaller than 5 ppm) together with the high quality MS/MS spectra, we identified the peak at m/z 6718 on the MALDI-TOF/TOF as N-term acetylated PEP-19 and ubiquitin-40S ribosomal protein S27a (Ubiquitin). The best fragmentation spectra corresponding to the two ions are displayed in Fig. 6A and 6C, validating the previous identifications assigned based on masses. The insert in Fig. 6A is the deconvoluted spectrum of the precursor ion at m/z 1120.05, showing its monoisotopic mass of 6714.25 Da. The original tandem MS spectrum is enlarged to exhibit the most abundant fragment ion y27 at m/z 997.875, which demonstrates the high mass accuracy and resolution of the Orbitrap Elite system we employed in this study. In the inserts of Fig. 6C, the precursor ion at m/z 1070.96 with a monoisotopic mass of 8559.61 Da gave rise to an abundant ion y20 at m/z 1141.37. The deconvoluted mass of this ion is calculated as 4561.45 Da, exhibiting merely a 0.01 Da mass error from the theoretical value. The high-quality tandem MS spectra led to high-confidence protein identification, facilitating future mechanistic studies on these proteins and related disease.

Inevitably, the same protein forms of high abundance were repeatedly selected for fragmentation within a single run. Therefore, increased cleavage site and improved fragmentation coverage were observed for all of the three fragmentation techniques. For example, the ion shown in Fig. 6B corresponds to acetylated PEP-19, identified with an E-value of 1.5E-77. Among all the fragmentation methods, HCD provided the most complete coverage for PEP-19 and enabled accurate localization of the acetylation site at the Serine of N-terminal; CID delivered comparable fragment ions in comparison to CID; whereas ETD produced ~1/3 of the number of the HCD fragment ions. As for ubiquitin, CID produced the most efficient fragmentation covering majority of the possible fragmentation sites, and CID produced slightly fewer fragment ions as displayed in Fig. 6D. Nevertheless, ETD again displayed merely ~1/3 of the fragment ions obtained from either HCD or CID. Fig. 6E illustrates the product ions generated by CID, HCD and ETD. ETD is a radical driven fragmentation technique and cleaves at N-Cα bond, which is distinct from those of HCD and CID. Therefore, ETD is complementary to HCD and CID fragmentation methods. This has been validated by comparing the fragmentation patterns produced by the three fragmentation techniques as shown in Fig. 6B and 6D. The utilization of all three fragmentation techniques significantly improves the coverage of the cleavage sites from the targeted proteins. The differentiating proteins displayed by MALDI-MS and identified by top-down tandem MS sequencing were listed in Table 1 with details presented in Table S1, whereas the proteins that displayed relatively the same abundance among groups via MALDI-MS yet identified by top-down sequencing were summarized in Table 2. A number of proteins, such as mitochondria import inner membrane translocase at m/z 10283, adenylate cyclases type 10 at m/z 9193, polyubiquitin at m/z 3468 and superoxide dismutase [Cu-Zn] at m/z 15825 were reported from the rat brain in a MALDI-MS setting for the first time. The identification of these proteins could provide valuable m/z information for other researchers that rely on MALDI-MS to discover protein biomarkers. A full list of identified proteins and corresponding fragment ions’ annotation based on high resolution top-down MS sequencing are detailed in Table S1, S2 in File S1 and File S2(top-down MSMS fragmentation).

Discussion

A Combined Profiling and Imaging Strategy for Biomarker Discovery and Screening

Our MALDI MS-based strategy combines MS profiling and imaging techniques with the goal to screen for changes in the distribution and relative abundance of proteins in the brains of rats that had experienced early developmental exposure to the NMDA antagonist MK801 on postnatal days 2 and 4. The profiling approach, which consists of manually depositing matrix on predefined substructures on a rat brain section, clearly highlights its advantages of speed, robustness and high reproducibility. Nevertheless, profiling also has the limitations that low spatial resolution is obtained for each region of interest. Alternatively, laser capture microdissection (LCM) technique is capable of isolating specific cell populations of interest from target tissue specimens, and has been combined with MSI for biomarker discovery by comparing spectra obtained from disease cells and normal cells [48,49]. Nonetheless, the administration of NMDA antagonists triggered cell apoptosis of great heterogeneity in developing brains as visualized by TUNEL [6]. Therefore, the LCM-captured cells might not be representative of all of the regions that might be perturbed during MK-801 treatment. Furthermore, molecular information of the un-profiled regions is lost. Complementary to rapid profiling by MS, the imaging approach delivers high spatial resolution MS images, allowing for further investigation of structural detail of the entire rat brain section. The utilization of software ClinProTools aids in raw data processing and statistical analysis to filter the spectral features that displayed significant changes in the MK801 and vehicle treated samples. Relying on the combined profiling and imaging strategy, elevated levels of ubiquitin, thymosin-β 4, PEP-19, acyl-CoA-binding protein subunits, cytochrome c oxidase subunits, mitochondrial import inner membrane translocase and adenylate cyclase type 10 were detected in the MK801-treated rat brains when compared to the vehicle-treated ones in the profiling spectra of selected brain regions. Moreover, MALDI-MSI affirmed increased abundance of these proteins by delivering high spatial resolution and high throughput MS images directly from the rat brain sections obtained from rats subjected to MK801 treatment. On the other hand, proteins that show decreased relative abundance levels in the MK801 treated rats were also observed, such as ATP synthase-coupling factor 6, ProSAAS, secretogranin, calmodulin and Superoxide dismutase [Cu-Zn]. Intriguingly, the
observation of these discriminating peaks in the MK801- and vehicle-treated rats might suggest involvement of the respective proteins in the pathological mechanisms of observed neurological deficits or in reparative processes. In contrast, the detection of proteins that displayed the same expression levels in the MK801 treated rats might imply that proteins from the treated subjects function normally as in the control group.

The spatial distribution of these differentially expressed proteins, determined by MS profiling and imaging techniques, corroborated with previous literature reporting massive apoptosis in the frontal and cingulate cortex following MK801 treatment of infant rats [6]. As shown in Figure 3E and 4E, significant differences could be observed in frontal and cingulate cortex for both ions, indicating that NMDA receptor blockade induced by MK801 during development might have led to severe neuronal loss in this region and triggered significant response of brain tissue in the form of protein expression level changes. Selective vulnerability of brain regions to MK801-induced imbalance could be attributed to a high level of NMDA receptors on neuronal populations within those regions [50]. The significant difference observed in the Acb region could also be attributed to a high concentration of NMDA receptors in Acb within the basal ganglia. However, receptor density cannot solely account for neuronal vulnerability. The NMDA receptor density together with additional factors, such as stage in synaptogenesis during treatment and the subunit composition of the NMDA receptor complex, combinatorially determine the degree of neuronal sensitivity [6]. This probably explains the significant changes observed in other regions, such as thalamus, cerebellum and olfactory bulb as shown in Figure 3E and 4E.

MALDI-MS Combined with High Resolution Top-down Tandem MS for Protein Identification

The subsequent step after biomarker screening is to unequivocally identify the protein targets of interest. We employed an MSI approach in combination with top-down tandem MS identification for this purpose. In a top-down proteomics experiment, protein identification is performed through intact mass measurement followed by tandem MS sequencing with high resolution mass accuracy FTMS-based platform. In comparison to bottom-up tandem MS sequencing, top-down tandem MS approach directly analyzes intact proteins [51] and best preserves the biological information observed by MALDI-MS [52]. It avoids the tedious mass correlation between intact protein masses observed on MSI and digested peptide masses detected by ESI-MS/MS. Moreover, it provides unique advantages in assessing protein modifications, such as PTMs and sequence variants, present in vivo with no prior knowledge [53,54]. The high-end instrument employed in this study offers superior mass accuracy in MS and MS/MS [55], which is highly advantageous for precise characterization of PTMs, and ultra high mass resolution, exemplified by the well-resolved whole protein isotopic distribution as shown in Fig. 6A and 6C. Combining with a standard fractionation step, we further purified the proteins of interest and unambiguously determined their identities by top-down tandem MS sequencing. Most of the protein targets observed by MALDI-MS were verified by the top-down approach and reliably mapped with full sequence coverage and PTMs. Other proteins were detected and identified, and are shown in the Table S1, S2 in File S1. The innovative protein identification strategy applied in this study, by combining the advantages of MALDI-MSI and top-down high resolution tandem MS, enables the identification of potential protein biomarkers for neuropsychiatric syndromes.

Figure 5. The workflow to identify the proteins that displayed changes in the MK801-treated samples. (A) MALDI-MS screening spectra of the HPLC fractions that contained the concentrated proteins of interest at m/z 6718 and 8566. (B) Representative MS spectrum acquired from a HPLC fraction containing the m/z 6718 ion on an ESI-Orbitrap Elite system, which provides ultra-high mass resolution and accuracy. The insert is the deconvoluted spectrum averaged from several multiply charged ion forms as highlighted in blue and red. (C) HCD, CID and ETD tandem MS fragmentation spectra of the particular ion at m/z 1120.05 (z = 6) highlighted in red.

doi:10.1371/journal.pone.0092831.g005
which result from excitatory/inhibitory neurotransmission imbalance in early development.

The ion signal at m/z 16792 in this study was identified as calmodulin and was also found to be N-terminally acetylated. In contrast to those upregulated proteins, MK801 treatment decreased the relative intensity of calmodulin in the rat brain compared to the vehicle-treated rats. Calmodulin is a major Ca\textsuperscript{2+}-binding protein in cells, where it complexes with Ca\textsuperscript{2+} and activates several types of intracellular enzymes, including kinases, phosphatases and adenylyl cyclases [56]. In its Ca\textsuperscript{2+} free form, calmodulin can also regulate the function of various proteins, like actin-binding and cytoskeletal proteins [57], making it essential in the regulation of cell structure. Failure of neuronal calcium homeostasis has been associated with cytotoxic events in the aging process and the pathogenesis of neurodegenerative diseases [58], since Ca\textsuperscript{2+}/calmodulin signaling is involved in controlling processes such as muscle contraction, neurotransmitter release, transcriptional regulation, and cell death [59,60]. More intriguingly, calmodulin has also been linked to the regulation of ion channels coupled to NMDA receptors [56].

Several intracellular peptides that contained an IQ motif were bestowed a unique ability to bind calcium-poor calmodulin, such as neuremodulin, neurogranin and PEP-19 [56]. PEP-19 can modulate Ca\textsuperscript{2+}/calmodulin homeostasis by altering the calcium-binding dynamics of free calmodulin and calmodulin bound to other target proteins. Interestingly, expression level changes of PEP-19 have been linked to several neurodegenerative conditions, such as Parkinson’s disease [29], Alzheimer’s disease [61] and Huntington’s disease [32]. Among the biological function studies of PEP-19, a study showing that PEP-19 can inhibit apoptotic cell death due to UV irradiation or treatment with staurosporine is of special interest [56]. Hence, the upregulation of PEP-19 in the MK801 treated samples could contribute to neuronal reparative processes.

Other than Ca\textsuperscript{2+}/calmodulin signaling, the ubiquitin pathway might also be involved in the molecular pathology of NMDA receptor antagonist neurotoxicity in developing rat brains. The increased abundance of ubiquitin observed in the MK801-treated group. Aberrations in the ubiquitin system have been linked with neurodegenerative diseases, such as Parkinson’s disease [62], Alzheimer’s disease [61,63], Huntington’s disease [64], Down’s Syndrome [63] or progressive supranuclear palsy [66]. Recently, ubiquitin gene networks expressed within the central nervous system have been postulated to contribute to the genetic susceptibility to ASD [67]. Previous literature also suggested that accumulation of ubiquitin could potentially result in dominant inhibition of the ubiquitin–proteasome system, leading to insufficient degradation of toxic proteins with neuropathological consequences.

The abundance of thymosin beta-4 was also elevated in rat brains subjected to MK801 treatment. Thymosin beta 4 (Tβ\textsubscript{4}) detected at m/z 4964 with N-term acetylation is a major actin monomer-sequestering molecule in mammalian cells. It has various biological functions, including regulation of inflammatory chemokines and cytokines, cellular migration, blood vessel formation and apoptosis [68]. It has been shown to prevent cell death from infections in the eye [69], loss of blood supply in the heart after myocardial infarction [70] and toxins in nerve cells [71]. For example, administration of thymosin beta has been shown to prevent the loss of hippocampal neurons after kainic acid treatment [71]. The significance of elevated abundance of Tβ\textsubscript{4} following MK801 treatment is unknown. It may be speculated that there is possible involvement of Tβ\textsubscript{4} in reparative processes, but its value as a potential therapeutic target ought to be evaluated in future research.

In this study, our results also revealed an intriguing increase of three cystochrome c oxidase (COX) subunits, i.e. the smallest subunit 7c at m/z 5486, the subunit 6c at m/z 8368 and the largest subunit 6b at m/z 9979, in the MK801 treated group, although the subunit 6c was not confirmed by top-down MS/MS spectra. The COX subunits reported here are mitochondrial respiratory chain (MRC) components, involved in electron transfer to oxygen [33]. COX is known to modulate apoptosis [72,73]. Previous studies have shown that an induction of MRC proteins like COX precede apoptosis induced by multiple stimuli. Specifically, increased expression of COX mRNAs and proteins were observed in apoptotic model systems such as Jurkat cells treated with camptothecin [74], breast cells treated with teniposide [74] and apoptotic epithelial cancer cells induced by chemical BMD188 [75]. The increased synthesis of MRC proteins, possibly representative of a more global mitochondrial activation response, is suggested to be responsible for subsequent disruption of MRC functions and ultimately cell death in response to apoptotic stimuli [72]. The up-regulation of COX subunits detected here could possibly be explained by this mechanism.

In conclusion, we have demonstrated that MALDI-MSI is capable of mapping the spatial distribution and relative abundance changes of multiple proteins simultaneously and directly from rat brain sections. The profiling strategy is fast, robust, and highly reproducible for producing proteome “snapshots” of the anatomical regions of interest in the infant rat brain sections. Complementary to this, the MSI technology enables more detailed molecular mapping with enhanced spatial resolution while increasing instrument time as a compromise. A combination of the two techniques allowed localization and assessment of the relative abundances of the biomolecules expressed in the MK801-treated and control samples with relatively high spatial resolution and reproducibility. The subsequent high mass spectral resolution top-down tandem MS approach allowed protein identification through accurate mass measurement of intact proteins followed by complementary fragmentation for tandem MS analysis. This hybrid approach showcases the unique abilities of MSI in the discovery of potential disease biomarkers. Relying on such a MSI-based platform, we have observed 22 proteins that exhibited differential relative abundance level changes upon NMDA receptor antagonist treatment such as PEP-19, ubiquitin, calmod-
ulcin, COX subunits. These potential biomarkers of excitatory/inhibitory neurotransmission imbalance-induced neurodevelopmental disorders reported in this pilot study are involved in Ca<sup>2+</sup>/calmodulin homeostasis, ubiquitin-proteasome system and mitochondria activation, possibly playing significant roles in brain neuron apoptosis or reparative processes. Collectively, this study opens up new avenues for future applications in the field of biomarker discovery and for mechanistic investigations delineating pathophysiology of neurodevelopmental disorders.

**Supporting Information**

**File S1** Method S1, On-line Top-down MS/MS on Nano-LC-ESI-LTQ-Orbitrap Elite. Table S1, Details of differentially-expressed rat brain proteins observed on MALDI-TOF/TOF and identified by top-down MS/MS sequencing. Table S2, Details of proteins identified merely by top-down MS/MS sequencing on nanoLC-ESI-LTQ-Orbitrap Elite.

**File S2** Top-down MSMS fragmentation. Fragment ions assignments of all the proteins identified by top-down MS/MS sequencing listed in the order as in Table 1/Table S1, Table 2 and Table S2.

**(XLS)**

**File S3** Top-down MSMS spectra. Raw top-down MS/MS spectra and fragmentation maps of all the proteins identified on nanoLC-ESI-LTQ-Orbitrap Elite listed in the order as they are shown in Table 1/Table S1, Table 2 and Table S2.

**(PDF)**

**Acknowledgments**

The authors thank Bruker Daltonics for graciously loaning the AutoFlex III MALDI TOF/TOF mass spectrometer.

**Author Contributions**

Conceived and designed the experiments: HY CI LL. Performed the experiments: HY CI LL. Analyzed the data: HY PMT LL. Contributed reagents/materials/analysis tools: AC PMT NK. Wrote the paper: HY CI LL.

**References**

1. Kaindl AM, Aminiahou S, Manthey D, Hagen MVD, Turski L, et al. (2006) Apoptotic signaling and the developing brain. Cell Mol Life Sci 63: 390–413.

2. Kaindl AM, Ikonomidou C (2007) Glutamate antagonists are neurotoxins for the developing brain. Neurotox Res 10: 203–218.

3. Gogolla N, LeBlanc JJ, Quast KB, Sudhof TC, Fagiolini M, et al. (2009) Common circuit defect of excitation-inhibition imbalance in mouse models of autism. J Neurodev Disord 1: 172–181.

4. Kaindl AM, Koppelstaetter A, Nebrich G, Stuew J, Säfström M, et al. (2008) Brief Alteration of NMDA or GABA(A) receptor-mediated neurotransmission has long term effects on the developing cerebral cortex. Mol Cell Proteomics 7: 2293–2310.

5. Stefkoska VG, Uckermann O, Czuczwar M, Smitka M, Czuczwar P, et al. (2008) Sedative and anticonvulsant drug suppress postnatal neurogenesis. Ann Neurol 64: 434–445.

6. Ikonomidou C, Bosch F, Miaka M, Bittinga P, Vockler J, et al. (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283: 70–74.

7. Teng PN, Hood BL, Sun M, Dhir R, Conrads TP (2011) Differential proteomic analysis of renal cell carcinoma tissue intrinsical fluid. J Proteome Res 10: 1333–1342.

8. Lowenthal MS, Mehta AI, Fogalke K, Bandle RW, Araujo RP, et al. (2005) Analysis of albumin-associated peptides and proteins from ovarian cancer patients. Clin Chem 51: 1933–1945.

9. Hu S, Ardellano M, Bouzahme P, Wang JH, Zhou H, et al. (2008) Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 14: 6246–6252.

10. Craig-Schapiro R, Perrin RJ, Roe CM, Xiao CJ, Carter D, et al. (2010) YKL-40: a novel prognostic blood biomarker for preclinical Alzheimer’s disease. Biol Psychiatry 68: 903–912.

11. Flint MS, Hood BL, Sun M, Stewart NA, Jones-Loughner J, et al. (2010) Proteomic analysis of the murine liver in response to a combined exposure to psychological stress and 7,12-dimethylbenz(a)anthracene. J Proteome Res 9: 509–520.

12. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pagnan F (2002) Genomics and the developing brain. Cell Mol Life Sci 63: 135–150.

13. Ishimura R, Ohkawasaka T, Sakaia M, Anki Y, et al. (2002) Altered protein profile and possible hypoxia in the placenta of 2,3β,7-trichlorohydrobenzo-p-dioxin-exposed rats. Toxicol Appl Pharmacol 150: 197–206.

14. Li TA, Xu SL, Oses-Prieto JA, Putil S, Xu P, et al. (2011) Proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 65: 509–520.

15. Hanrieder J, Ljungdahl A, Falth M, Mammo SE, Bergquist J, et al. (2011) L-Arginine-induced dyskinesia is associated with regional increase of striatal dopaminergic peptides as elicitated by imaging mass spectrometry. Mol Cell Proteomics 10: M110.005991.

16. Dekeyser SS, Kutz-Naber KK, Schmidt JJ, Barrett-Wilt GA, Li L (2007) Mass spectral imaging of neuropeptides in crustacea nerve tissue by MALDI TOF/TOF. J Proteome Res 6: 1782–1791.

17. Pirman DA, Reich RF, Kiss A, Heeren RM, Yost RA (2012) Quantitative MALDI tandem mass spectrometric imaging of cocaine from brain tissue with a deuterated internal standard. Anal Chem 85: 1081–1089.

18. Minaveia L, Clerasoa S, Baggerrman G, Arckena I (2008) Direct profiling and identification of peptide expression differences in the pancreas of control and ob/ob mice by imaging mass spectrometry. Proteomics 8: 3763–3774.

19. Skold K, Svensson M, Nilsson A, Zhang XQ, Nydalh K, et al. (2006) Decreased striatal levels of PEP-19 following MPTP lesion in the mouse. J Proteome Res 5: 262–269.

20. Hanrieder J, Ljunghald A, Faith M, Mammo SE, Bergquist J, et al. (2011) L-DOPA-induced dyskinesia is associated with regional increase of striatal dopamine peptides as elicitated by imaging mass spectrometry. Mol Cell Proteomics 10: M111.009308.

21. Li J, Hummon AB (2011) Imaging mass spectrometry of three-dimensional cell culture systems. Anal Chem 83: 8794–8801.

22. Udal AK, Stokopa AL, Roy M, Coleman PD (1999) PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington’s disease. Neuroscience 88: 993–993.

23. Eimer M, Rauser S, Maier S, Schone C, Balluff B, et al. (2012) MALDI imaging mass spectrometry reveals COX/TA2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett’s adenocarcinoma. J Proteomics dx.doi.org/10.1016/j.jprot.2012.02.012.

24. Balluff B, Rauser S, Medling S, Eimer M, Schone C, et al. (2011) MALDI imaging identifies prognostic seven protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 179: 2720–2729.

25. Delbosc S, Haloué M, Louedec L, Dupuis M, Cubizolles M, et al. (2008) Proteomic analysis permits the identification of new biomarkers of arterial wall remodeling in hypertension. Mol Med 14: 303–304.
36. Hardesty WM, Keiley MC, Mi D, Low RL, Caprioli RM (2011) Protein signatures for survival and recurrence in metastatic melanoma. J Proteomics 74: 1002–1014.
37. Debos D, Bertrand V, Quinlon L, De Paue-Gillet MC, De Paue E (2010) MALDI on-source decay applied to mass spectrometry imaging: a new tool for protein identification. Anal Chem 82: 4036–4045.
38. Groseclose MR, Anderson M, Hardesty WM, Caprioli RM (2007) Identification of proteins directly from tissue: in situ tryptic digests coupled with imaging mass spectrometry. J Mass Spectrom 42: 254–262.
39. Wang Z, Han J, Schey KL (2008) Spatial differences in an integral membrane proteome detected in laser capture microdissected samples. J Proteome Res 7: 2969–2976.
40. Rauscher S, Marquardt C, Ballaff B, Deininger SO, Albers C, et al. (2010) Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. J Proteome Res 9: 1854–1863.
41. Meistermann H, Norris JL, Arni HR, Cornett DS, Friedlein A, et al. (2006) Biomarker discovery by imaging mass spectrometry: transthyretin is a biomarker for gentamicin-induced nephrotoxicity in rat. Mol Cell Proteomics 5: 1076–1086.
42. Debois D, Smargiasso N, Demeure K, Asakawa D, Zimmerman TA, et al. (2013) MALDI in-source decay, from sequencing to imaging. Top Curr Chem 317: 111–141.
43. Lagarrigue M, Alexandrov T, Dietes G, Perrin A, Lavigne R, et al. (2012) New biomarker discovery with MSI in developing brain. J Proteome Res 11: 5435–5463.
44. Schey KL, Anderson DM, Rose KL (2013) Spatially-directed protein identification from tissue sections by top-down LC-MS/MS with electron transfer dissociation. Anal Chem 85: 6767–6774.
45. Stella DR, Floyd KA, Grey AC, Renfrow MB, Schey KL, et al. (2010) Tissue localization and solubilities of α-crystallin and its numerous C-terminal truncation products in pre- and postcataractaric ICR/rat lenses. Invest Ophthalmol Vis Sci 51: 5153–5161.
46. Bora A, Annangudi SP, Millet LJ, Rubakhin SS, Forbes AJ, et al. (2008) Neuropeptidomics of the supraoptic rat nucleus. J Proteome Res 7: 4992–5003.
47. Pierson J, Norris JL, Arni HR, Svenningson P, Caprioli RM, et al. (2004) Molecular profiling of experimental Parkinson’s disease: direct analysis of peptides and proteins on brain tissue sections by MALDI mass spectrometry. J Proteome Res 3: 209–295.
48. Feldkirchner S, Schesel J, Muller S, Schoser B, Hahnisch FG (2012) Patient-specific protein aggregates in myofibrillar myopathies: laser microdissection and differential proteomics for identification of plaque components. Proteomics 12: 3598–3609.
49. Xu BJ, Caprioli RM, Sanders ME, Jensen RA (2002) Direct analysis of laser capture microdissected cells by MALDI mass spectrometry. J Am Soc Mass Spectrom 13: 1292–1297.
50. Monaghan DT, Coton CW (1985) Distribution of N-methyl-D-aspartate-sensitive L-[H-3]glutamate-binding sites in rat brain. J Neurosci 5: 2909–2919.
51. Kelleher NL (2004) Top-down proteomics. Anal Chem 76: 196a–203a.
52. Sampson JS, Murray KK, Muddiman DC (2009) Intact and top-down characterization of biomolecules and direct analysis using infrared matrix-assisted laser desorption electrospray ionization coupled to FT-ICR mass spectrometry. J Am Soc Mass Spectrom 20: 667–673.
53. Ferguson JT, Wengen CD, Metcalf WW, Kelleher NL (2009) Top-down proteomics reveals novel protein forms expressed in Methanosarcina acetivorans. J Am Soc Mass Spectrom 20: 1743–1750.
54. Zhang J, Sun JS, Ge T, Yang Z, Zhou J, et al. (2010) Discriminating modifications in swine cardiac troponin I by top-down high-resolution tandem mass spectrometry. J Am Soc Mass Spectrom 21: 949–949.
55. Michalski A, Damoc E, Langy O, Denisov E, Nolting D, et al. (2012) Ultra high resolution linear ion trap orbitrap mass spectrometer (Orbitrap Elite) facilitates top down LC MS/MS and versatile peptide fragmentation modes. Mol Cell Proteomics 11: O111.0136098.
56. Johanson RA, Sarau HM, Fodey JJ, Slommon JR (2000) Calmodulin-binding peptide PFP-19 modulates activation of calmodulin kinase II In situ. J Neurosci 20: 2860–2866.
57. Beckingham K, Lu AQ, Andruss BF (1998) Calcium-binding proteins and development. Biometals 11: 359–373.
58. Pereira CF, Oliveira CR (2000) Oxidative glutamate toxicity involves mitochondrial dysfunction and perturbation of intracellular Ca2+ homeostasis. Neurosci Res 37: 227–236.
59. Berriage MJ, Bootman MD, Roderick HL (2003) Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol 4: 517–529.
60. Montei EH, McAndrew D, Faddy HM, Roberts-Thomson SJ (2007) Calcium and cancer: targeting Ca2+ transport. Nat Rev Cancer 7: 519–530.
61. Slommon JR, Hughes CM, Campbell GA, Flood DG (1994) Increased levels of homoglutaminase and other peptides in Alzheimer’s disease cerebral cortex. J Neurosci 14: 2223–2233.
62. McNaught KS, Olano CW, Hallwell B, Isacson O, Jenner P (2001) Failure of the ubiquitin-proteasome system in Parkinson’s disease. Nat Rev Neurosci 2: 589–594.
63. Lam YA, Pickart CM, Alban A, Landon M, Jimison C, et al. (2000) Inhibition of the ubiquitin-proteasome system in Alzheimer’s disease. Proc Natl Acad Sci USA 97: 9902–9906.
64. Bennett EJ, Shaler TA, Woodman B, Ryu KY, Zaitseva TS, et al. (2007) Global changes to the ubiquitin system in Huntington’s disease. Nature 448: 704–708.
65. van Leeuwen FW, de Kleijn DP, van den Hurk HH, Neuhauer A, Sonnemans MA, et al. (1998) Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer’s and Down patients. Science 279: 242–247.
66. Ferguson J, Landon M, Love J, Ward L, van Leeuwen FW, et al. (2000) Neurofilibryl tangles in progressive supranuclear palsy brains exhibit immunoreactivity to frameshift mutant ubiquitin-B protein. Neurosci Lett 279: 69–72.
67. Glesser JT, Wang K, Cai G, Kovatsa O, Kim CE, et al. (2009) Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature 459: 569–573.
68. Philip D, Kleinman HK (2010) Animal studies with thymosin beta 4, a multifunctional tissue repair and regeneration peptide. Ann N Y Acad Sci 1194: 81–86.
69. Sonne G, Siddiqi A, Kurpakus-Wheater M (2004) Thymosin-beta 4 inhibits corneal epithelial cell apoptosis after ethanol exposure in vitro. Invest Ophthalmol Vis Sci 45: 1095–1100.
70. Badamchian M, Fagarasan MO, Danner RL, Suffredini AF, Damavandy H, et al. (2003) Thymosin beta 4 reduces lethality and down-regulates inflammatory mediators in endotoxin-induced septic shock. Int Immunopharmacol 3: 1225–1233.
71. Popoli P, Pepponi R, Martire A, Armida M, Pezzola A, et al. (2007) Neuropeptidic effects of thymosin beta 4 in experimental models of excitotoxicity. Ann N Y Acad Sci 1112: 219–224.
72. Chandra D, Liu JW, Tang DG (2002) Early mitochondrial activation and cytochrome c up-regulation during apoptosis. J Biol Chem 277: 50842–50854.
73. Huttermann M, Lee I, Grossman LI, Doan JW, Sanderson TH (2012) Phosphorylation of mammalian cytochrome c and cytochrome c oxidase in the regulation of cell destiny: respiration, apoptosis, and human disease. Adv Exp Med Biol 748: 237–264.
74. Sanchez-Alcazar JA, Khodjakov A, Schneider E (2001) Anticancer drugs induce corneal epithelial cell apoptosis after ethanol exposure in vitro. Invest Ophthalmol Vis Sci 45: 1095–1100.
75. Joshi B, Li L, Taffe BG, Zhu Z, Wahl S, et al. (1999) Apoptosis induction by a novel anti-prostate cancer compound, BMD188 (a fatty acid-containing hydroxamic acid), requires the mitochondrial respiratory chain. Cancer Res 59: 4343–4355.